Pase2, Paragraph3. 3):
3． Background, purpose, and basis of the rights offering
3) In October 2007, we licensed the development and marketing rights worldwide excluding Japan for DACH-platin micelle (NC-4016) to Debiopharm S.A., and that has organized a phase I clinical trial is underway in Europe. However, in September 2010, Debiopharm S.A. notified us that this agreement will be terminated for strategic reasons of business strategy in Debiopharm. (the agreement will be conclude effectively terminated in March 2011). With the conclusion termination of the agreement, we will have exclusive worldwide development and marketing rights in addition to exclusive manufacturing right we have. As DACH-platin micelle is in the phase I clinical trial, from the results of pre-clinical, and possibly clinical trial, we expect license agreements on favorable terms and to quickly acquire new partners. Another phase I clinical trial is also planned in Japan and will cost about 220 million yen.
Detail of Correction due to translation error